NEW YORK (GenomeWeb News) – Belgian molecular diagnostic company Multiplicom today announced a deal with French institutes ICM and ICAN to develop molecular diagnostic tests for the identification of genetic mutations associated with cardiovascular, metabolic, and neurological diseases.
Multiplicom will pair its expertise on MDx test development using massive parallel sequencing with ICM and ICAN's disease knowledge and well-documented samples to develop and validate the tests. Multiplicom will commercialize any products resulting from the partnership, which as a first project is developing a test for the early onset of diabetes. Additional projects will follow, the company said.
Based in Antwerp, Belgium, Multiplicom designs, develops, and commercializes MDx tests based on massively parallel sequencing. Last year, it raised about $3 million. ICM and ICAN are hospital-university institutes at Hôpital Pitié Salpêtrière in Paris.